Oral L-carnitine and Inflammatory and Nutritional Biomarkers in Maintenance Hemodialysis

Summary

The goal of this clinical trial is to evaluate whether oral L-carnitine supplementation helps reduce inflammation and improve nutritional status in patients with end-stage kidney disease who are undergoing long-term hemodialysis. A total of 50 participants will be randomly assigned to receive either: * Oral L-carnitine solution (1 g, three times per week after dialysis), or * A placebo solution that looks and tastes the same but does not contain L-carnitine. The study will last for three months. Researchers will assess changes in: * Inflammatory markers (high-sensitivity C-reactive protein, hs-CRP) * Nutritional markers (serum albumin, ferritin) * Blood lipid profile (cholesterol, LDL, HDL, triglycerides) The findings from this study are expected to provide insights into the potential clinical benefits of oral L-carnitine supplementation in maintenance hemodialysis patients.

Timeline

Start

2020-11-30

Primary completion

2021-02-28

Completion

2021-03-08

Drugs

Indications